S.Collins HIV i-Base UK-CAB November 2005 UK-CAB November 2005 Feedback from 7th Lipodystrophy Workshop 13-16 November, Dublin.

Slides:



Advertisements
Similar presentations
Louis Haenel, IV, DO Endocrinology. Terminology Lipodystrophy Lipoatrophy Lipohypertrophy HIV HAART (Highly Active Anti-Retroviral Therapy)
Advertisements

LMULMU Corresponding Author: Thomas Sternfeld, MD Medizinische Poliklinik, University of Munich Pettenkoferstr. 8a Munich Germany Phone:
Metabolic Complications of HIV Dr Lou Haenel, Jr Endocrinology 12/10.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Dyslipidemia/Lipid management in Diabetes. M ECHANISMS R ELATING I NSULIN R ESISTANCE AND D YSLIPIDEMIA  TG  Apo B  VLDL (hepatic lipase) Kidney (CETP)CEHDL.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Simvastatin Increases HDL-C and Apolipoprotein A-1 Levels Significantly More Than Atorvastatin John P. Kastelein, Evan A. Stein, Michael A. Davidson, John.
TM © 1999 Professional Postgraduate Services ® S: Total Mortality Reduction in a Subgroup of Patients With Diabetes Proportion.
Comparison of PI vs PI  ATV/r vs DRV/rATADAR. ATV/r 300/100 mg + TDF/FTC qd N = 91 N = 89 DRV/r 800/100 mg + TDF/FTC qd  Design Randomisation 1: 1 Open-label.
Case Presentation Managing treatment side effects in the correctional environment Stephen Tabet, MD, MPH University of Washington Division of Infectious.
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
CE-1 CRESTOR ® Clinical Development Efficacy James W. Blasetto, MD, MPH Senior Director, Clinical Research.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
Obesity M.A.Kubtan MD - FRCS M.A.Kubtan1. 2  Pulmonary Disease  Fatty Liver Disease  Orthopedic Disorders  Gallbladder Disease  Psychological Impact.
START study: UK-CAB July2015 Community feedback: START study Simon Collins HIV i-Base
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
UK-CAB August 2003 Conference Feedback For 6th UK-CAB 8th August 2003 Simon Collins HIV i-Base.
A Randomised, Open-Label Comparative Trial of Abacavir or Tenofovir DF as Replacement for a Thymidine Analogue in Persons with Lipoatrophy and Suppressed.
Leptin Replacement Therapy Improves Insulin Resistance in Highly Active Antiretroviral Therapy (HAART) Induced Lipodystrophy and Metabolic Syndrome in.
Preferred treatment options for patients with Diabetes Dr Jon Tuppen GPwSI Beechwood Surgery Brentwood.
Changes in Lipids in Randomised, Open-Label Comparative Trial of Abacavir or Tenofovir DF as Replacement for a Thymidine Analogue in Persons with Lipoatrophy.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
URIDINE FOR THE TREATMENT OF HAART- ASSOCIATED LIPODYSTROPHY - a randomized, double-blind, placebo-controlled trial.
HIV i-Base: SMART Study & CROI Feedback UK-CAB - Feb 2006 UK-CAB 24 February 2006 CROI Feedback: SMART Study Simon Collins.
A Randomized Placebo- Controlled Trial of Metformin for the Treatment of HIV Lipodystrophy Rakhi Kohli MD MS, Christine Wanke MD, Sherwood Gorbach MD,
Lipodystrophy Impact of HIV 第 22 回日本エイズ学会教育セッション David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of.
A.P.J. Houdijk Euro Weight Loss-2015 Frankfurt, Germany August 18 – 20, 2015.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
The 2 nd International AIDS Society Conference on HIV Pathogenesis and Treatment July 13-16, 2003; Paris, France Selected and summarized by Douglas J.
A Diabetes Outcome Progression Trial
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
02-15 INFC Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study* 1 Date of preparation:
A randomized open study comparing the impact of reducing stavudine dose vs. switching to tenofovir on mitochondrial function, metabolic parameters, and.
© 2004, Wellsource Inc. Low Carbohydrate Diet and LDL Cholesterol Levels 119 men and women, 24 weeks On the low carb diet, LDL increased slightly On low.
Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.
Polypill x Aspirin Project Groups 3 and 4
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
1 Joint NDAC/EMDAC Meeting January 13, 2005 Mevacor TM Daily 20 mg Tablets Rx-to-OTC Switch Daiva Shetty, M.D. Division of Over-the-Counter Drug Products.
The Heart Outcomes Prevention Evaluation (HOPE) – 3 Trial
Novel Antiretroviral Studies and Strategies
Switch to PI/r monotherapy
Title slide.
TDF-FTC vs. ABC-3TC, each with Atazanavir + RTV or Efavirenz ACTG 5224s (Bone Effects): Study Design
XVI International AIDS Conference
Switch from EFV plus ABC-3TC to EFV-TDF-FTC ROCKET-1 Trial
The American Heart Association Presented by Dr. Steven E. Nissen
Down regulation of genes controlling fatty acid metabolism and anaerobic respiration in subcutaneous adipose tissue after months antiviral treatment.
Decrease in Intra-Abdominal Visceral Fat May Reduce Blood Pressure in Obese Hypertensive Women by Hideyuki Kanai, Katsuto Tokunaga, Shigenori Fujioka,
Diabetes Health Status Report
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
Switch to BIC/FTC/TAF GS-US GS-US GS-US
Section 7: Aggressive vs moderate approach to lipid lowering
Switch to RAL-containing regimen - Canadian Study - CHEER - Montreal Study - EASIER - SWITCHMRK - SPIRAL.
Switch to LPV/r monotherapy
Screening, Lipid Stabilization, and Placebo Run-in
Switch to BIC/FTC/TAF GS-US GS-US GS-US
Switch to DRV/r monotherapy
Comparison of NNRTI vs PI/r
Switch to RAL-containing regimen
Switch to LPV/r monotherapy
Switch to ATV- or ATV/r-containing regimen
Comparison of PI vs PI ATV vs ATV/r BMS 089
Major classes of drugs to reduce lipids
Switch to LPV/r monotherapy
Comparison of NRTI combinations
Comparison of NRTI combinations
ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.
Section 6: Update on lipid treatment guidelines
Presentation transcript:

S.Collins HIV i-Base UK-CAB November 2005 UK-CAB November 2005 Feedback from 7th Lipodystrophy Workshop November, Dublin

S.Collins HIV i-Base UK-CAB November 2005 Treatments: uridine, pravastatin, facial fat after switch, Niacin ER, buttock implants, Other: monitoring access programmes, Polypill, NVP and brown fat, heart disease Mechanisms: are fat loss and fat accumulation caused by a single process; nevirapine and brown fat Q&As throughout please Overview

S.Collins HIV i-Base UK-CAB November 2005 Uridine - for people on AZT or d4T Pravastatin - showed fat return Niacin ER - no reduction in VAT Switch - RAVE analysis showed return of facial fat Buttock implants - first reports - not a simple process Treatments/Interventions

S.Collins HIV i-Base UK-CAB November 2005 Randomised trial: 36g, 3x day for first 10 days of each month, for 3 ~£60/month 20 people on d4T- or AZT-regimens randomised to NucleomaxX or placebo Limb fat, total fat and intra-abdominal fat all inc. vs placebo and baseline (~ g) HDL fell (1.24 to 1.15mmol/). No effect on TG, lactates and insulin resistance (Sutinen et al. Abs 7) Study 2: 16 pts, 36gTID every other day for 16 wks - no∆ mtDNA in fat or PBMC, only pt and doc survey (MacComsey et al. Abs 82) Uridine (NucleomaxX)

S.Collins HIV i-Base UK-CAB November men on stable PI; TC>6.5 (median =7.6) 4 week dietary advice: randomised to PVS (40mg/day) or placebo for 16 weeks No change AUC cholesterol from baseline Modest changes from week 4 Total fat and limb fat both increase and % IAF decreased (Malon et al. Abs 23) Pravastatin

S.Collins HIV i-Base UK-CAB November 2005 PVSplacebop Chol AUC 0-16 week Chol AUC 4-16 week Total fat kg Limb fat kg % IAF (Mallon et al. Abs 23) Pravastatin

S.Collins HIV i-Base UK-CAB November 2005 Sub-study (n=47) from UK RAVE study: switch from AZT or d4T to TDF (n=23) or ABC (n=24) 39/47 with facial LA at baseline; no reported benefit from pts in either arm Mean volume difference (3D scan) at wk 48 was +2539mm3 (both cheeks) and +0.36kg (limb fat change, DEXA) Correlation between increases in cheek and limb; no differences between TDF and ABC (Benn et al. Abs 8) Switch (RAVE)

S.Collins HIV i-Base UK-CAB November wk multi-centre open label study in 33 men with TG >200mg/dl (67% white) 500mg titrations every 4-6 weeks up to target 2000mg/day (n=23 reached 2000mg/day; 8 reached 1500mg/day) No reduction seen in VAT (not in abstract) Caution careful monitoring for glucose regulation and liver (Dubé et al. Abs 12) Niacin ER

S.Collins HIV i-Base UK-CAB November 2005 baseline%∆wk24%∆wk48 Total-C * HDL-C * TG * Non-HDL-C * * P <0.01 (Dubé et al. Abs 12) Niacin ER

S.Collins HIV i-Base UK-CAB November 2005 Spanish plastic surgery dept Rarely reported at Lipo Workshops Report on 7 women Used silicone implants, placed inside muscle Satisfied by results but no with contrast to thin legs MRI scans for safety - will require replacement (Fontdevila et al. Abs 41) Buttock implants

S.Collins HIV i-Base UK-CAB November 2005

Monitoring access programmes Monitoring side effects: harm vs safety Polypill - INSIGHT group (ld aspirin, lisinopril (ACE inhibitor to lower BP), hydrochlorithiazide (diuretic), pravastatin (cholesterol lowering). nevirapine and brown fat Risk of cardiovascular disease Other

S.Collins HIV i-Base UK-CAB November 2005 Reversal of fat loss also increased intra-abdominal fat (IAF - also known as VAT = visceral adipose tissue) Analysed lipoatrophy studies: MITOX (and ROSEY) - male, 72 weeks, symptomatic lipoatrophy, DEXA If limb fat increased, VAT tended to increase. If VAT decreased, limb fat tended to decrease. Different risk factors (Wand et al. Abs 3) Single mechanism?

S.Collins HIV i-Base UK-CAB November 2005

NVP brown fat gene expression Brown fat cellWhite fat cell

S.Collins HIV i-Base UK-CAB November 2005 Biopsies from lipoma from HIV- and HIV+ +/- HAART In vitro study of brown pre-adipocytes in culture exposed to individual ARVs Gene expression related to brown fat was then measured in cultures and biopsies Gene for preferentially expressing brown fat partially determined in lipoma, and markers (UCP- 1) were activated by d4T and nevirapine (and suppressed by efavirenz, nelfinavir, saquinavir) NVP brown fat gene expression

S.Collins HIV i-Base UK-CAB November 2005 Incremental risk of heart disease x 1.5 x 2.3 x 3.5 x 3.9 x 5.9 x 2.7 x 1.7 Smoking Hypertension Dyslipideamia